Search for: "Eli, Inc." Results 381 - 400 of 1,001
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
11 Jul 2012, 10:02 pm by Linda Moss
The three drugs in final tests, according to AP, are: Bapineuzumab, from Pfizer Inc. and Johnson & Johnson; Solanezumab, from Eli Lilly & Co.; and Gammagard, from Baxter International Inc. [read post]
12 Mar 2013, 5:43 pm by Lawrence B. Ebert
Eli Lilly & Co., 598 F.3d 1336, 1340 (Fed. [read post]
25 Feb 2015, 8:03 am
Opening Address: Professor Emily Michiko Morris, IU McKinney School of Law, The Changing Landscape in Biopharmaceuticals 9:00 - 10:15 Panel One: University Tech Transfers in BioPharma Chad Pittman, Vice President, Purdue Research Foundation James Myers, JD, PhD, Eli Lilly Professor Greg Dolin, University of Baltimore School of Law Moderator: Constance Lindman, Partner, SmithAmundsen 10:30 - 11:45 Panel Two: Legal Issues in Clinical Trials (US and Asia) Professor Rebecca S. [read post]
3 Sep 2013, 6:11 am by Staci Zaretsky
[Tuscaloosa News] * Legal commentators like Elie and Lat would be ecstatic if law school were two years long, but because so many others have a “vested interest in the status quo,” change will come at approximately half past never. [read post]
5 Sep 2014, 7:48 am
" The evening will begin with the Bedel Financial Consulting, Inc. cocktail reception at 5:30 p.m., followed by dinner, fashion show and the Citizens Energy Group after party. [read post]
21 Dec 2020, 2:56 pm by Lawrence B. Ebert
The outcome: Apotex, Inc. appeals from the judgment of the district court in a patent-infringement suit brought by Eli Lilly & Company under the Hatch-Waxman Act, 21 U.S.C. [read post]
9 Oct 2014, 9:00 am by Ashley S. O'Neill
A California federal court will hold a trial on this novel question in Cellular Accessories For Less, Inc. v. [read post]
25 Feb 2015, 8:49 am
Opening Address: Professor Emily Michiko Morris, IU McKinney School of Law, The Changing Landscape in Biopharmaceuticals 9:00 - 10:15 Panel One: University Tech Transfers in BioPharma Chad Pittman, Vice President, Purdue Research Foundation James Myers, JD, PhD, Eli Lilly Professor Greg Dolin, University of Baltimore School of Law Moderator: Constance Lindman, Partner, SmithAmundsen 10:30 - 11:45 Panel Two: Legal Issues in Clinical Trials (US and Asia) Professor Rebecca S. [read post]
12 Dec 2013, 7:12 am
In short, where the patent holder has already obtained an SPC on the basis of a patent protecting an innovative active ingredient and a marketing authorisation for a medicinal product containing that ingredient as the single active ingredient, and that SPC entitles him to oppose the use of that active ingredient, either alone or in combination with other active ingredients, Article 3(c) of the SPC Regulation must be interpreted as precluding that patent holder from obtaining –- on the basis of… [read post]
18 Oct 2009, 9:17 pm
By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. [read post]
31 Aug 2010, 10:01 pm by Kelly
Apotex Inc. et al (Docket Report) Lovenox (Enoxaparin) – US: DC District Court denies preliminary injunction in generic Lovenox case; Is the juice worth the squeeze for Sanofi to appeal? [read post]
28 Nov 2008, 12:49 pm
victories in fight for European BRCA patents (Holman's Biotech IP Blog) Europe: European Commission proposes strategy for dealing with rare diseases (Pharmacapsules @ Gowlings) US: Former House Ways and Means Economist claims 7-year data exclusive period is sufficient (Patent Docs) US: Medco predicts follow-on biologics regulatory pathway by 2011 (Patent Docs) US: Even after patent has expired, District Court has jurisdiction to set exclusivity date: In re Omeprazole Patent Litigation… [read post]